Equibles does not estimate personal net worth.
Get an email with a short summary when Harmony Biosciences Holdings, Inc. publishes a filing, an earnings call transcript or a press release.
Get HRMY alertsPeter Anastasiou is recorded as CEO at Harmony Biosciences Holdings, Inc. (HRMY) since January 1, 2027, COO at Harmony Biosciences Holdings, Inc. (HRMY) since April 2, 2026 and Board Member at Harmony Biosciences Holdings, Inc. (HRMY) since November 5, 2023. Harmony Biosciences Holdings, Inc. reported in an 8-K filed October 13, 2026 that Peter Anastasiou was appointed Class I director, effective January 1, 2027. Harmony Biosciences Holdings, Inc. reported in an 8-K filed October 13, 2026 that Peter Anastasiou was appointed President and Chief Executive Officer, effective January 1, 2027. Harmony Biosciences Holdings, Inc. reported in an 8-K filed April 2, 2026 that Peter Anastasiou resigned as director. Equibles holds 6 filed executive changes naming Peter Anastasiou; each is listed under recent activity with its source filing. Peter Anastasiou has spoken on 2 earnings calls across 1 company, most recently for Harmony Biosciences Holdings, Inc. on November 4, 2026. Harmony Biosciences Holdings, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Harmony Biosciences Holdings, Inc. includes Jeffrey Dayno (CEO), Jeffrey M. Dayno (CEO and Board Member), Jeffrey S. Aronin (Chairman) and 7 others.
“In addition, the Board appointed Mr. Anastasiou as a Class I director of the Company, effective as of the Appointment Effective Date, to fill the vacancy resulting from Dr. Dayno’s resignation from the Board, with a term expiring at the Company’s 2027 Annual Meeting of Stockholders and until his successor is elected and qualified, or until his earlier death, resignation or removal.”
“On October 12, 2026, the Company announced that Peter Anastasiou, the Company’s current Chief Operating Officer, has been appointed by the Board to serve as President and Chief Executive Officer of the Company, effective as of January 1, 2027, at 12:00 a.m. Eastern Time (the “Appointment Effective Date”).”
“First, I want to thank Jeff for his leadership and for everything he has done for Harmony over the last nine years. Wakex is on track to exceed a billion in net revenues this year.”
“In business development, we are primarily focused on assets with revenue potential in the 2028 to 2032 time frame. We are prioritizing products in phase three, in registration, or on the market.”
2027-01-01–present
2026-04-02–present
2023-11-05–present
2023-11-05–2026-04-02
Biotechnology · Healthcare
CEO, COO, Board Member
2023-11-05–present
